Lysoganglioside GM1 Antibody, IgG
The Lysoganglioside GM1 receptor (Lyso GM1) Antibody, IgG assay measures the antibody titer against the neuronal antigen Lysoganglioside GM1 and compares this measurement to a normal control titer against Lysoganglioside GM1. Study of patients with Sydenham chorea revealed IgG antibodies directed against the group A streptococcal carbohydrate epitope GlcNAc and also against lysoganglioside and GM1 ganglioside but not to other gangliosides. The anti-neuronal autoantibodies found in the serum and cerebrospinal fluid of Sydenham chorea patients also signaled SK-N-SH human neuronal cells in culture to activate the calcium calmodulin protein kinase II (CaMKII) inside the human neuronal cells when treated with the human monoclonal antibodies (mAbs), serum antibodies (IgG) or cerebrospinal fluid antibodies (IgG). It was also shown that lysoganglioside blocked the binding of the serum or cerebrospinal fluid IgG to the caudate putamen region of human brain. During convalescence, these autoimmune antibodies receded to normal levels. The results revealed that improvement of patient symptoms was associated with reduction in anti-lysoganglioside antibody and the reduction of CaMKII antibody-mediated signaling of human neuronal cells.
These remarkable findings from Sydenham chorea patients was published for the first time in *Nature Medicine* in 2003. In 2006, a similar study of a PANDAS patient sera was published in the *Journal of Neuroimmunology*. This showed that the antibodies (IgG) in PANDAS patient sera also reacted with lysoganglioside and signaled molecules at the surface of human neuronal cells to activate the CaMKII enzyme in the human neuronal cells. These studies showed that lysoganglioside could inhibit the reaction of the serum or cerebrospinal fluid antibodies (IgG) reactivity with human caudate putamen brain tissue from human basal ganglia. CSF from PANDAS patients also contained these same IgG antibodies, which signaled human neuronal cells to activate the CaMKII. These results in humans suggest an antibody-mediated mechanism in disease.
The Lysoganglioside GM1 (LYSO-GM1) Antibody, IgG is one of the five tests which comprise The Cunningham Panel™ of Tests. The Cunningham Panel™ tests measure human serum Immunoglobulin G (IgG) levels by Enzyme-Linked ImmunoSorbent Assay (ELISA) directed against: Dopamine D1 Receptor (DRD1), Dopamine D2L Receptor (DRD2L), Lysoganglioside-GM1 (LYSO-GM1) and Tubulin (TUB). ELISA results are determined by measuring the colorimetric intensity at a specific wavelength which is directly proportional to the amount of antibody in the sample. The fifth assay of this panel measures the specific activity of calcium/calmodulin-dependent protein kinase II (CaM KII) induced by the patient’s serum in cultured human neuronal cell lines compared to controls. This panel measures the level of these antibodies, and the ability of the patient’s sera to stimulate CaM KII at a single point in time. The Cunningham Panel™ of Tests is a proprietary test panel exclusively offered by Moleculera Labs. For more information please see .
| Anti-Dopamine Receptor D1 (titer) | Anti-Dopamine Receptor D2L (titer) | Anti-Lysoganglioside GM1 (titer) | Anti-Tubulin (titer) | CaM Kinase II (% of baseline) | |
| Normal Ranges | 500 - 2,000 | 2,000 - 8,000 | 80 - 320 | 250 - 1,000 | 53 - 130 |
| Normal Mean | 1,056 | 6,000 | 147 | 609 | 95 |
Serum (Red top tube).
4-5 mL serum collected in red-top glass tube with no additives or gel barrier. Ship on two fully frozen 8-ounce ice packs, overnight only Monday-Thursday. Do not ship on Friday or before a US holiday.
Stability
- Frozen: 1 year
- J Child Adolesc Psychopharmacol. 2015;25(1):76-85. [PMID: 25658702]
- J Child Adolesc Psychopharmacol. 2015;25(1):3-13. [PMID: 25325534]
- Nature Medicine. 2003;9(7):914-920. [PMID: 12819778]
- PLoS One. 2013;8(9):e73516. [PMID: 24073196]
- Acta Physiol (Oxf). 2016;216(1):90-100. [PMID: 26454143]
- Immunology. 2007;178:7412-7421. [PMID: 17513792]